Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 9Sarcoma 4Breast 2Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Breast Cancer Metastatic 1

Interventions

Trastuzumab 242Paclitaxel 223Fulvestrant 196Capecitabine 182Docetaxel 164Letrozole 142pembrolizumab 115Carboplatin 100exemestane 98Gemcitabine 98Cyclophosphamide 92palbociclib 86Anastrozole 83pertuzumab 78Lapatinib 73Bevacizumab 71ribociclib 68130-nm albumin-bound paclitaxel 66abemaciclib 59eribulin 58Doxorubicin 55Vinorelbine 51Injections 47Ado-Trastuzumab Emtansine 47Tamoxifen 45Everolimus 44Albumin-Bound Paclitaxel 44atezolizumab 35trastuzumab deruxtecan 34Nivolumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × nirogacestat × Breast × Clear all
NCT01876251 2019-03-15

A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer

Pfizer

Phase 1 Terminated
30 enrolled 29 charts
Breast

Breast Cancer Metastatic

NCT02299635 2019-01-08

A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations

Pfizer

Phase 2 Terminated
19 enrolled 9 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡